keyword
MENU ▼
Read by QxMD icon Read
search

fluoxetine bipolar

keyword
https://www.readbyqxmd.com/read/27738380/treatment-resistant-depression-with-loss-of-antidepressant-response-rapid-acting-antidepressant-action-of-dextromethorphan-a-possible-treatment-bridging-molecule
#1
Edward C Lauterbach
Dextromethorphan (DM) may have ketamine-like rapid-acting, treatment-resistant, and conventional antidepressant effects.(1,2) This reports our initial experience with DM in unipolar Major Depressive Disorder (MDD). A patient with treatment-resistant MDD (failing adequate trials of citalopram and vortioxetine) with loss of antidepressant response (to fluoxetine and bupropion) twice experienced a rapid-acting antidepressant effect within 48 hours of DM administration and lasting 7 days, sustained up to 20 days with daily administration, then gradually developing labile loss of antidepressant response over the ensuing 7 days...
August 15, 2016: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/27686028/lamotrigine-compared-to-placebo-and-other-agents-with-antidepressant-activity-in-patients-with-unipolar-and-bipolar-depression-a-comprehensive-meta-analysis-of-efficacy-and-safety-outcomes-in-short-term-trials
#2
Marco Solmi, Nicola Veronese, Leonardo Zaninotto, Marc L M van der Loos, Keming Gao, Ayal Schaffer, Catherine Reis, Claus Normann, Ion-George Anghelescu, Christoph U Correll
OBJECTIVES: To meta-analytically summarize lamotrigine's effectiveness and safety in unipolar and bipolar depression. METHODS: We conducted systematic PubMed and SCOPUS reviews (last search =10/01/2015) of randomized controlled trials comparing lamotrigine to placebo or other agents with antidepressant activity in unipolar or bipolar depression. We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs)...
October 2016: CNS Spectrums
https://www.readbyqxmd.com/read/27559347/effect-of-fluoxetine-consumption-on-orthodontic-tooth-movement-in-rats
#3
Amir Hossein Mirhashemi, Mohammad Sadegh Ahmad Akhoundi, Sedigheh Sheikhzadeh, Nafiseh Momeni, Ahmadreza Dehpour, Mojgan Alaeddini, Yasaman Kheirandish, Homa Farhadifard, Elahe Ansari
OBJECTIVES: Fluoxetine is a selective serotonin re-uptake inhibitor (SSRI) widely used for depression, bipolar disorder, anxiety and obsessive-compulsive disorder. The aim of this study was to assess the effect of fluoxetine on orthodontic tooth movement (OTM) in rats. MATERIALS AND METHODS: Forty-five male Wistar rats were randomly divided into three groups namely the control group (no medication), saline and fluoxetine dissolved in saline. In all groups, nickel titanium closed-coil spring was used between the left maxillary central incisor and first molar to exert 60g force at 2mm activation...
December 2015: Journal of Dentistry of Tehran University of Medical Sciences
https://www.readbyqxmd.com/read/27400221/quetiapine-related-rabbit-syndrome-in-a-patient-with-bipolar-depression-and-treated-with-olanzapine-fluoxetine-combination
#4
H Belli, M Akbudak, Z E Bal
Rabbit syndrome is an extrapyramidal side effect which is described as a variant of tardive dyskinesia. Rabbit syndrome is characterized by rapid, rhytmic orofacial movements, often accompanied by lip sounds. This movement disorder may be associated with either typical or atypical antipsychotic agents. The index case presented to our clinic with the complaints of bipolar depression. In addition to valproate, quetiapine was started with the dose of 50 mg per day, which was increased to 300 mg per day within two weeks for depression...
December 14, 2015: West Indian Medical Journal
https://www.readbyqxmd.com/read/27270858/comparing-clinical-responses-and-the-biomarkers-of-bdnf-and-cytokines-between-subthreshold-bipolar-disorder-and-bipolar-ii-disorder
#5
Tzu-Yun Wang, Sheng-Yu Lee, Shiou-Lan Chen, Yun-Hsuan Chang, Liang-Jen Wang, Po See Chen, Shih-Heng Chen, Chun-Hsien Chu, San-Yuan Huang, Nian-Sheng Tzeng, Chia-Ling Li, Yi-Lun Chung, Tsai-Hsin Hsieh, I Hui Lee, Kao Chin Chen, Yen Kuang Yang, Jau-Shyong Hong, Ru-Band Lu
Patients with subthreshold hypomania (SBP; subthreshold bipolar disorder) were indistinguishable from those with bipolar disorder (BP)-II on clinical bipolar validators, but their analyses lacked biological and pharmacological treatment data. Because inflammation and neuroprogression underlies BP, we hypothesized that cytokines and brain-derived neurotrophic factor (BDNF) are biomarkers for BP. We enrolled 41 drug-naïve patients with SBP and 48 with BP-II undergoing 12 weeks of pharmacological treatment (valproic acid, fluoxetine, risperidone, lorazepam)...
June 7, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27079776/bipolar-depression-managing-patients-with-second-generation-antipsychotics
#6
Lindsay M Avery, Shannon J Drayton
Bipolar affective disorder is a debilitating illness that manifests as cyclical episodes of mood elevation and depression, but the treatment of the depressive episodes (i.e., bipolar depression) differs considerably from the treatment of major depressive disorder. In bipolar affective disorder, it is well known that patients spend a significantly greater amount of time in depressive episodes than manic or hypomanic episodes, yet there are currently just three Food and Drug Administration-approved agents for the treatment of bipolar depression: (1) olanzapine/fluoxetine combination (2) quetiapine, both immediate- and extended-release, and (3) lurasidone...
2016: International Journal of Psychiatry in Medicine
https://www.readbyqxmd.com/read/27036122/lurasidone-an-antipsychotic-with-antidepressant-effects-in-bipolar-depression
#7
Nicholas A Keks, Judy Hope, David Castle
OBJECTIVE: Lurasidone is a new serotonin-dopamine antagonist atypical antipsychotic which also appears to be effective in bipolar depression. This paper will briefly review the evidence concerning lurasidone. CONCLUSIONS: Lurasidone is an antagonist at dopamine D2, serotonin 5-HT2 and 5-HT7, and partial agonist at 5HT1a receptors; it has no anticholinergic or antihistaminic activity. Rapidly absorbed, it has a half-life of 18 ± 7 hours, will reach steady state in five days and is taken at night with food (absorption is halved on an empty stomach)...
June 2016: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/26952895/treating-bipolar-depression-antidepressants-and-alternatives-a-critical-review-of-the-literature
#8
Antonio Tundo, Paola Cavalieri, Serena Navari, Fulvia Marchetti
OBJECTIVE: Although depressive symptoms are preponderant in the course of bipolar (BP) disorders, the treatment of BP depression remains a controversial issue with different clinical approaches available. This review addresses the issues of whether antidepressants (ADs) are effective in treating acute and long-term BP depression, risks linked to ADs and what alternatives to ADs are available. METHODS: We searched the MEDLINE databases using the following syntax: [bipolar depression AND unipolar depression AND (antidepressants OR anticonvulsants OR lithium OR antipsychotics OR dopamine-agonists OR psychoeducation OR psychotherapy OR electroconvulsive therapy OR transcranial magnetic stimulation)]...
June 2011: Acta Neuropsychiatrica
https://www.readbyqxmd.com/read/26938817/state-of-the-art-psychopharmacological-treatment-options-in-seasonal-affective-disorder
#9
REVIEW
Mesut Yildiz, Sedat Batmaz, Emrah Songur, Esat Timuçin Oral
Seasonal affective disorder (SAD) is defined as a subtype of mood disorders in DSM 5, and it is characterized by a seasonal onset. SAD is proposed to be related to the seasonal changes in naturally occurring light, and the use of bright light therapy for depressive symptoms has been shown to reduce them in placebo controlled trials. Cognitive behavioral therapy has also been demonstrated to be effective in SAD. This review article aims to focus on the psychopharmacological treatment options for SAD. According to clinical trial results, first line treatment options seem to be sertraline and fluoxetine, and are well tolerated by the patients...
March 2016: Psychiatria Danubina
https://www.readbyqxmd.com/read/26703328/-is-it-her-hormones-psychiatric-diagnoses-and-polycystic-ovarian-syndrome
#10
Ann Genovese, Teri Smith, Holly Kramer, Marilyn Augustyn
Beth, whom you have cared for in your primary care practice since she was born, is a 15-year-old adolescent girl with no prior psychiatric history who developed significant symptoms of clinical depression, associated with self-injurious behavior (cutting on wrists, arms, and thighs). She denied any known precipitant for her depression.She is a ninth grade honors student in the gifted program at a local high school and is described as a talented musician, playing multiple musical instruments as well as soccer and basketball...
January 2016: Journal of Developmental and Behavioral Pediatrics: JDBP
https://www.readbyqxmd.com/read/26615849/evaluations-of-the-absolute-and-relative-free-energies-for-antidepressant-binding-to-the-amino-acid-membrane-transporter-leut-with-free-energy-simulations
#11
Chunfeng Zhao, David A Caplan, Sergei Yu Noskov
The binding of ligands to protein receptors with high affinity and specificity is central to many cellular processes. The quest for the development of computational models capable of accurately evaluating binding affinity remains one of the main goals of modern computational biophysics. In this work, free energy perturbation/molecular dynamics simulations were used to evaluate absolute and relative binding affinity for three different antidepressants to a sodium-dependent membrane transporter, LeuT, a bacterial homologue of human serotonin and dopamine transporters...
June 8, 2010: Journal of Chemical Theory and Computation
https://www.readbyqxmd.com/read/26521087/lower-3h-ly341495-binding-to-mglu2-3-receptors-in-the-anterior-cingulate-of-subjects-with-major-depressive-disorder-but-not-bipolar-disorder-or-schizophrenia
#12
Caitlin E McOmish, Geoff Pavey, Andrew Gibbons, Shaun Hopper, Madhara Udawela, Elizabeth Scarr, Brian Dean
INTRODUCTION: The glutamatergic system has recently been implicated in the pathogenesis and treatment of major depressive disorders(MDD) and mGlu2/3 receptors play an important role in regulating glutamatergic tone. We therefore measured cortical levels of mGlu2/3 to determine if they were changed in MDD. METHODS: Binding parameters for [(3)H]LY341495 (mGlu2/3 antagonist) were determined to allow optimized in situ binding with autoradiography to be completed using a number of CNS regions...
January 15, 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/26488347/parotid-salivary-parameters-in-bulimic-patients-a-controlled-clinical-trial
#13
Elżbieta Paszyńska, Agnieszka Słopień, Monika Węglarz, Roger W A Linden
OBJECTIVES: The aim of this study was to determine whether patients with purging-type bulimia and/or non-bulimic patients, treated with serotonin reuptake inhibitor SI-5-HT (fluoxetine), have dental erosion and changes in selected buffer components of parotid saliva (bicarbonates, phosphates, urea), compared with the healthy population. METHODS: A controlled clinical trial was designed for three, age-matched, female groups of 94 patients: 1) bulimic patients treated with fluoxetine 40 mg/day (n = 25), 2) non-bulimic patients diagnosed with bipolar affective disorder, treated with fluoxetine 20mg/day (n = 25), and 3) healthy controls (n = 44)...
2015: Psychiatria Polska
https://www.readbyqxmd.com/read/26475745/changes-in-muscarinic-m2-receptor-levels-in-the-cortex-of-subjects-with-bipolar-disorder-and-major-depressive-disorder-and-in-rats-after-treatment-with-mood-stabilisers-and-antidepressants
#14
Andrew Stuart Gibbons, Won Je Jeon, Elizabeth Scarr, Brian Dean
BACKGROUND: Increasingly, data are implicating muscarinic receptors in the aetiology and treatment of mood disorders. This led us to measure levels of different muscarinic receptor-related parameters in the cortex from people with mood disorders and the CNS of rats treated with mood stabilisers and antidepressant drugs. METHODS: We measured [(3)H]AF-DX 384 binding in BA 46 and BA 24 from subjects with bipolar disorders (n = 14), major depressive disorders (n = 19), as well as age- and sex-matched controls (n = 19) and the CNS of rats treated with fluoxetine or imipramine...
April 2016: International Journal of Neuropsychopharmacology
https://www.readbyqxmd.com/read/26425446/pharmacologic-approaches-to-treatment-resistant-depression-evidences-and-personal-experience
#15
Antonio Tundo, Rocco de Filippis, Luca Proietti
AIM: To review evidence supporting pharmacological treatments for treatment-resistant depression (TRD) and to discuss them according to personal clinical experience. METHODS: Original studies, clinical trials, systematic reviews, and meta-analyses addressing pharmacological treatment for TRD in adult patients published from 1990 to 2013 were identified by data base queries (PubMed, Google Scholar e Quertle Searches) using terms: "treatment resistant depression", "treatment refractory depression", "partial response depression", "non responder depression", "optimization strategy", "switching strategy", "combination strategy", "augmentation strategy", selective serotonin reuptake inhibitors antidepressants (SSRI), tricyclic antidepressants (TCA), serotonin norepinephrine reuptake inhibitors antidepressants, mirtazapine, mianserine, bupropione, monoamine oxidase inhibitor antidepressant (MAOI), lithium, thyroid hormones, second generation antipsychotics (SGA), dopamine agonists, lamotrigine, psychostimulants, dextromethorphan, dextrorphan, ketamine, omega-3 fatty acids, S-adenosil-L-metionine, methylfolat, pindolol, sex steroids, glucocorticoid agents...
September 22, 2015: World Journal of Psychiatry
https://www.readbyqxmd.com/read/26341077/paroxetine-suppresses-recombinant-human-p2x7-responses
#16
Phuong Dao-Ung, Kristen K Skarratt, Stephen J Fuller, Leanne Stokes
P2X7 receptor (P2X7) activity may link inflammation to depressive disorders. Genetic variants of human P2X7 have been linked with major depression and bipolar disorders, and the P2X7 knockout mouse has been shown to exhibit anti-depressive-like behaviour. P2X7 is an ATP-gated ion channel and is a major regulator of the pro-inflammatory cytokine interleukin 1β (IL-1β) secretion from monocytes and microglia. We hypothesised that antidepressants may elicit their mood enhancing effects in part via modulating P2X7 activity and reducing inflammatory responses...
December 2015: Purinergic Signalling
https://www.readbyqxmd.com/read/26316760/lurasidone-for-the-treatment-of-bipolar-depression-an-evidence-based-review
#17
REVIEW
Rachel Franklin, Sam Zorowitz, Andrew K Corse, Alik S Widge, Thilo Deckersbach
Bipolar disorder (BD) is a debilitating and difficult-to-treat psychiatric disease that presents a serious burden to patients' lives as well as health care systems around the world. The essential diagnostic criterion for BD is episodes of mania or hypomania; however, the patients report that the majority of their time is spent in a depressive phase. Current treatment options for this component of BD have yet to achieve satisfactory remission rates. Lurasidone is a drug in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 for the acute treatment of bipolar depression...
2015: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/26256011/lurasidone-and-fluoxetine-reduce-novelty-induced-hypophagia-and-nmda-receptor-subunit-and-psd-95-expression-in-mouse-brain
#18
COMPARATIVE STUDY
Tiberiu Loredan Stan, Vasco Cabral Sousa, Xiaoqun Zhang, Michiko Ono, Per Svenningsson
Lurasidone, a novel second-generation antipsychotic agent, exerts antidepressant actions in patients suffering from bipolar type I disorder. Lurasidone acts as a high affinity antagonist at multiple monoamine receptors, particularly 5-HT2A, 5-HT7, D2 and α2 receptors, and as a partial agonist at 5-HT1A receptors. Accumulating evidence indicates therapeutic actions by monoaminergic antidepressants are mediated via alterations of glutamate receptor-mediated neurotransmission. Here, we used mice and investigated the effects of chronic oral administration of vehicle, lurasidone (3 or 10mg/kg) or fluoxetine (20mg/kg) in the novelty induced hypophagia test, a behavioral test sensitive to chronic antidepressant treatment...
October 2015: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/26042634/efficacy-and-tolerability-of-treatments-for-bipolar-depression
#19
Gustavo H Vázquez, Jessica N Holtzman, Leonardo Tondo, Ross J Baldessarini
BACKGROUND: Depression in bipolar disorder is a major therapeutic challenge associated with disability and excess mortality. METHODS: We reviewed findings from randomized placebo-controlled trials concerning efficacy and adverse effects of treatments for acute bipolar depression, including anticonvulsants, antidepressants, lithium, and modern antipsychotics, to compare numbers-needed-to-treat (NNT) versus -to-harm (NNH). RESULTS: Included were data from 22 reports involving 33 drug-placebo pairs...
September 1, 2015: Journal of Affective Disorders
https://www.readbyqxmd.com/read/26035060/chronic-administration-of-anticonvulsants-but-not-antidepressants-impairs-bone-strength-clinical-implications
#20
P W Gold, M G Pavlatou, D Michelson, C M Mouro, M A Kling, M-L Wong, J Licinio, S A Goldstein
Major depression and bipolar disorder are associated with decreased bone mineral density (BMD). Antidepressants such as imipramine (IMIP) and specific serotonin reuptake inhibitors (SSRIs) have been implicated in reduced BMD and/or fracture in older depressed patients. Moreover, anticonvulsants such as valproate (VAL) and carbamazepine (CBZ) are also known to increase fracture rates. Although BMD is a predictor of susceptibility to fracture, bone strength is a more sensitive predictor. We measured mechanical and geometrical properties of bone in 68 male Sprague Dawley rats on IMIP, fluoxetine (FLX), VAL, CBZ, CBZ vehicle and saline (SAL), given intraperitoneally daily for 8 weeks...
June 2, 2015: Translational Psychiatry
keyword
keyword
119254
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"